For research use only
| Cat No. | ABC-TC3900 |
| Product Type | Diseased Human Peripheral Blood Mononuclear Cells |
| Cell Type | Mononuclear Cell |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Peripheral Blood |
| Disease | Normal |
| Storage | Liquid Nitrogen |
Human Mobilized Peripheral Blood Mononuclear Cells provide enriched mononuclear fractions for immunology studies, cell therapy, and cytokine assays.
Human Mobilized Peripheral Blood Mononuclear Cells (PBMCs) are isolated from peripheral blood following cytokine-induced mobilization (typically with G-CSF), which triggers hematopoietic stem cells (HSCs) to egress from bone marrow into circulation. These cells represent a heterogeneous population that develops through hematopoietic differentiation, containing lymphocytes (T cells, B cells, NK cells), monocytes, and trace dendritic cells, but excluding granulocytes and erythrocytes. Morphologically, these cells are mainly mononuclear with round to oval nuclei, they typically grow in suspension in vitro. These PBMCs express typical lineage markers such as CD3 (T cells), CD19 (B cells), CD56 (NK cells), and CD14 (monocytes). Functionally, they are the core of immune response: T cells participate in antigen-specific killing and immune regulation, B cells secrete antibodies, NK cells mediate the clearance of nonspecific tumor/virus-infected cells, and monocytes perform antigen presentation and phagocytosis after differentiation.
| Species | Human |
| Cat.No | ABC-TC3900 |
| Product Category | Primary Cells |
| Size/Quantity | 1 vial |
| Cell Type | Mononuclear Cell |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Peripheral Blood |
| Disease | Normal |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Diseased Human Peripheral Blood Mononuclear Cells |
| Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
Human Mobilized Peripheral Blood Mononuclear Cells (PBMCs) serve as powerful tools for advanced immunotherapy development and translational research, particularly in hematopoietic stem cell expansion, adoptive cell therapy manufacturing, and GVHD studies, where their mobilization-activated state improves cell yields and functionality for ex vivo engineering and drug screening applications. Researchers leverage these cells for their increased CD34⁺ content and immune cell activation in cancer immunotherapy protocols, vaccine development, and immune reconstitution studies, providing critical advantages over conventional PBMCs in cell therapy pipelines and preclinical models.
When you publish your research, please cite our product as "AcceGen Biotech Cat.# XXX-0000". In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).